Dexmedetomidine and Esketamine in Perioperative Neurocognitive Disorders: Mechanistic Plausibility, Trial Evidence and Evidential Reliability

Review History

Published: 2026-11-18

DOI: 10.9734/bpi/psrtc/v3/8221

Page: 19-59


P. Sharmila *

Department of Anaesthesiology, SRM MCH&RC, India.

*Author to whom correspondence should be addressed.


Abstract

Background: Perioperative neurocognitive disorders, including postoperative delirium, delayed neurocognitive recovery and postoperative neurocognitive disorder, are frequent and consequential in older surgical patients, yet no drug is recommended by guideline panels for routine prophylaxis. Dexmedetomidine, a selective alpha-2 adrenoceptor agonist, and esketamine, the S-enantiomer of ketamine and an N-methyl-D-aspartate receptor antagonist, have become the two most intensively investigated candidates, and the two drugs are increasingly administered together.

Aim and Scope: This critical narrative review examines whether the mechanistic rationale and clinical evidence for dexmedetomidine, esketamine and their combination justify claims of neurocognitive protection in adult surgical patients, with particular attention to the reliability of the underlying evidence.

Approach: Literature was identified through structured searches of bibliographic databases, full-text repositories, citation indexes and a trial registry, supplemented by citation tracking and checks for retractions, and was appraised qualitatively and synthesised thematically.

Principal Findings: Mechanistic support for both drugs derives largely from animal models and surrogate biomarkers, and the clinical relevance of these signals remains unproven. For dexmedetomidine, benefit against postoperative delirium appears most consistent when the drug acts during the postoperative or overnight period in older non-cardiac surgical patients, whereas large placebo-controlled cardiac trials have been neutral, and pooled estimates are sensitive to risk of bias, publication bias and the inclusion of subsequently retracted trials. For esketamine, meta-analyses report substantial reductions in early delirium, but the evidence base is geographically concentrated, short in follow-up, inconsistent across larger trials and difficult to reconcile with the neutral results of racemic ketamine. Evidence for the combination is limited to small single-centre trials that rarely isolate the contribution of each component.

Unresolved Questions: Optimal timing, dose, patient selection, effects on cognition beyond 30 days, and the roles of sleep, analgesia and mood as mediators remain uncertain.

Conclusion: Neither agent, alone or in combination, can presently be regarded as an established neuroprotective intervention. Adequately powered, multicentre, prospectively registered trials with standardised outcome ascertainment and longer cognitive follow-up are required before routine prophylactic use can be justified.

Keywords: Postoperative delirium, delayed neurocognitive recovery, alpha-2 adrenergic receptor agonists, N-methyl-D-aspartate receptor antagonists, neuroinflammation, perioperative sleep, older surgical patients, research integrity


How to Cite

Sharmila, P. (2026). Dexmedetomidine and Esketamine in Perioperative Neurocognitive Disorders: Mechanistic Plausibility, Trial Evidence and Evidential Reliability. Pharmaceutical Science: Research Trends and Challenges Vol. 3, 19–59. https://doi.org/10.9734/bpi/psrtc/v3/8221